JP Morgan Chase
DNTH icon

JP Morgan Chase’s Dianthus Therapeutics DNTH Stock Holding History

JP Morgan Chase’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.54M Sell
31,938
-10,701
-25% -$620K ﹤0.01% 3926
2025
Q4 		$1.76M Sell
42,639
-25,485
-37% -$988K ﹤0.01% 4175
2025
Q3 		$2.68M Buy
68,124
+58,746
+626% +$1.5M ﹤0.01% 3860
2025
Q2 		$175K Sell
9,378
-2,305
-20% -$43.2K ﹤0.01% 5300
2025
Q1 		$212K Sell
11,683
-446
-4% -$9.83K ﹤0.01% 5212
2024
Q4 		$264K Buy
12,129
+1,490
+14% +$38.3K ﹤0.01% 5359
2024
Q3 		$291K Buy
10,639
+412
+4% +$11.5K ﹤0.01% 5222
2024
Q2 		$265K Sell
10,227
-5,791
-36% -$139K ﹤0.01% 5005
2024
Q1 		$481K Buy
16,018
+15,977
+38,968% +$347K ﹤0.01% 4816
2023
Q4 		$426 Hold
41
– – ﹤0.01% 6948
2023
Q3 		$560 Sell
41
-3
-7% -$38 ﹤0.01% 6710
2023
Q2 		$533 Hold
44
– – ﹤0.01% 6539
2023
Q1 		$1K Hold
44
– – ﹤0.01% 6511
2022
Q4 		$0 Sell
44
-155
-78% -$2.74K ﹤0.01% 6625
2022
Q3 		$4K Sell
199
-28,729
-99% -$787K ﹤0.01% 6132
2022
Q2 		$555K Buy
28,928
+1,183
+4% +$29.2K ﹤0.01% 4485
2022
Q1 		$1.29M Buy
27,745
+4,454
+19% +$243K ﹤0.01% 4089
2021
Q4 		$1.65M Sell
23,291
-8,898
-28% -$894K ﹤0.01% 4001
2021
Q3 		$3.75M Buy
32,189
+2,814
+10% +$328K ﹤0.01% 3282
2021
Q2 		$4.6M Sell
29,375
-124
-0.4% -$22.8K ﹤0.01% 3124
2021
Q1 		$5.59M Buy
29,499
+10,500
+55% +$1.77M ﹤0.01% 2871
2020
Q4 		$2.38M Buy
18,999
+13,283
+232% +$1.51M ﹤0.01% 3357
2020
Q3 		$625K Sell
5,716
-7,019
-55% -$832K ﹤0.01% 3880
2020
Q2 		$1.53M Buy
12,735
+9,179
+258% +$1.29M ﹤0.01% 3273
2020
Q1 		$357K Buy
3,556
+491
+16% +$91K ﹤0.01% 4000
2019
Q4 		$743K Buy
3,065
+2,671
+678% +$499K ﹤0.01% 4039
2019
Q3 		$65K Buy
394
+60
+18% +$11.4K ﹤0.01% 5057
2019
Q2 		$79K Buy
334
+115
+53% +$28.4K ﹤0.01% 5009
2019
Q1 		$58K Buy
219
+158
+259% +$27.3K ﹤0.01% 5074
2018
Q4 		$6K Buy
61
+3
+5% +$409 ﹤0.01% 5513
2018
Q3 		$11K Buy
+58
New +$12.2K ﹤0.01% 5493

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase's DNTH Position: Q1 2026 in Review

JP Morgan Chase reduced its Dianthus Therapeutics (DNTH) stake by 25% in Q1 2026, selling an estimated $620K and leaving 31,938 shares worth $2.54M. The position accounts for ﹤0.01% of the portfolio, ranked #3926.

JP Morgan Chase first reported a position in DNTH in Q3 2018 and has held it in 31 quarters since. The position peaked at $5.59M in Q1 2021. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • JP Morgan Chase held 31,938 shares of Dianthus Therapeutics worth $2.54M as of Q1 2026.
  • JP Morgan Chase sold 10,701 Dianthus Therapeutics shares in Q1 2026, an estimated $620K.
  • Dianthus Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3926 holding.
  • JP Morgan Chase first reported a position in Dianthus Therapeutics in Q3 2018 and has held it in 31 quarters since.
  • JP Morgan Chase's Dianthus Therapeutics position peaked at $5.59M in Q1 2021.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.